Esophageal Disorders Clinical Trials

A listing of Esophageal Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 304 clinical trials
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (DG-03)

chemotherapy and/or immunotherapy in HER2-positive advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients. Study hypotheses: Combination of T-DXd with

metastatic adenocarcinoma
fluorouracil
metastasis
pembrolizumab
adenocarcinoma
  • 0 views
  • 08 Jul, 2022
  • 51 locations
Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA1)

Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic …

Accepts healthy volunteers
  • 0 views
  • 13 Jun, 2022
  • 1 location
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC). Sub study 02 - Cohort B1, B2 and B3 would

esophageal cancer
squamous cell carcinoma
gastrointestinal cancer
cancer
EGFR
  • 0 views
  • 27 Jul, 2022
  • 29 locations
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

percentage of patients experiencing an objective response in the setting of advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC). Sub study 02 - Cohort B1, B2 and B3 would

esophageal cancer
squamous cell carcinoma
gastrointestinal cancer
cancer
EGFR
  • 5 views
  • 05 Aug, 2022
  • 33 locations
Futibatinib in Patients With Specific FGFR Aberrations

-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.

  • 1 views
  • 23 Jul, 2022
  • 57 locations
PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects

The purpose of this study is to characterize the pharmacokinetics (PK) and safety of intravenous (IV) pantoprazole in patients 1 to 16 years old who are candidates for acid suppression therapy.

pantoprazole
  • 61 views
  • 10 Jul, 2022
  • 8 locations
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom

  • 9 views
  • 01 Jul, 2022
  • 36 locations
Onco-primary Care Networking to Support TEAM-based Care (ONE TEAM)

The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a dynamic treatment regimen approach. The investigators propose to randomize 800 adults with newly-diagnosed selected cancers treated …

cancer care
cancer
diabetes
cardiovascular disease
chronic disease
  • 0 views
  • 09 Jun, 2022
  • 1 location
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

This study is a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms will enroll subjects in parallel to characterize the safety, tolerability, PK, …

squamous cell carcinoma of head and neck
cancer
EGFR
progressive disease
measurable disease
  • 19 views
  • 11 Apr, 2022
  • 8 locations
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.

  • 297 views
  • 28 Jul, 2022
  • 12 locations